Flavone-8-acetic acid (flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury in vivo

Flavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA on platelet-dependent thrombosis was studied in vivo in the porcine carotid artery after deep arterial injury by balloon angioplasty. (111)In-labeled au...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 101; no. 3; pp. 324 - 328
Main Authors MRUK, J. S, WEBSTER, M. W. I, HERAS, M, REID, J. M, GRILL, D. E, CHESEBRO, J. H
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 25.01.2000
American Heart Association, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Flavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA on platelet-dependent thrombosis was studied in vivo in the porcine carotid artery after deep arterial injury by balloon angioplasty. (111)In-labeled autologous platelet and (125)I-labeled porcine fibrin(ogen) deposition, and the incidence of macroscopic mural thrombosis onto deeply injured artery (tunica media) were compared in 20 pigs (40+/-1 kg [mean+/-SEM], body surface area=1.0+/-0.1 m(2)), randomized to FAA bolus (n=10) of 5.5g/m(2), followed by an infusion at 0.14g. m(-2). min(-1) or placebo (n=10). Vasoconstriction was measured immediately beyond the dilated segment using quantitative angiography. Platelet deposition (x10(6)/cm(2) of carotid artery) was reduced over 12-fold in pigs treated with FAA (13+/-3 versus 164+/-51, P=0.001) compared with placebo. Fibrin(ogen) deposition (x10(12) molecules/cm(2) of carotid artery) did not significantly differ in FAA-treated pigs versus placebo (40+/-8 versus 140+/-69, P=0.08). Large mural thrombi were present in 100% of placebo-treated pigs versus very small thrombi in 40% of FAA-treated pigs (P=0.005). Vasoconstriction was reduced from 46+/-6% in the placebo group to 15+/-3% in the FAA group (P<0.001). Plasma level of FAA before angioplasty was 515+/-23 microgram/mL. The activated partial thromboplastin time was unchanged. The bleeding time was >2SD above the normal mean in 4 of 5 treated pigs (increased from 157+/-29 to 522+/-123 s). FAA markedly reduced platelet deposition, mural thrombi, and injury-induced vasoconstriction after deep arterial injury, suggesting that a major inhibition of platelet glycoprotein Ibalpha may be beneficial therapy.
AbstractList BACKGROUNDFlavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA on platelet-dependent thrombosis was studied in vivo in the porcine carotid artery after deep arterial injury by balloon angioplasty.METHODS AND RESULTS(111)In-labeled autologous platelet and (125)I-labeled porcine fibrin(ogen) deposition, and the incidence of macroscopic mural thrombosis onto deeply injured artery (tunica media) were compared in 20 pigs (40+/-1 kg [mean+/-SEM], body surface area=1.0+/-0.1 m(2)), randomized to FAA bolus (n=10) of 5.5g/m(2), followed by an infusion at 0.14g. m(-2). min(-1) or placebo (n=10). Vasoconstriction was measured immediately beyond the dilated segment using quantitative angiography. Platelet deposition (x10(6)/cm(2) of carotid artery) was reduced over 12-fold in pigs treated with FAA (13+/-3 versus 164+/-51, P=0.001) compared with placebo. Fibrin(ogen) deposition (x10(12) molecules/cm(2) of carotid artery) did not significantly differ in FAA-treated pigs versus placebo (40+/-8 versus 140+/-69, P=0.08). Large mural thrombi were present in 100% of placebo-treated pigs versus very small thrombi in 40% of FAA-treated pigs (P=0.005). Vasoconstriction was reduced from 46+/-6% in the placebo group to 15+/-3% in the FAA group (P<0.001). Plasma level of FAA before angioplasty was 515+/-23 microgram/mL. The activated partial thromboplastin time was unchanged. The bleeding time was >2SD above the normal mean in 4 of 5 treated pigs (increased from 157+/-29 to 522+/-123 s).CONCLUSIONSFAA markedly reduced platelet deposition, mural thrombi, and injury-induced vasoconstriction after deep arterial injury, suggesting that a major inhibition of platelet glycoprotein Ibalpha may be beneficial therapy.
Background —Flavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA on platelet-dependent thrombosis was studied in vivo in the porcine carotid artery after deep arterial injury by balloon angioplasty. Methods and Results — 111 In-labeled autologous platelet and 125 I-labeled porcine fibrin(ogen) deposition, and the incidence of macroscopic mural thrombosis onto deeply injured artery (tunica media) were compared in 20 pigs (40±1 kg [mean±SEM], body surface area=1.0±0.1 m 2 ), randomized to FAA bolus (n=10) of 5.5g/m 2 , followed by an infusion at 0.14g · m −2 · min −1 or placebo (n=10). Vasoconstriction was measured immediately beyond the dilated segment using quantitative angiography. Platelet deposition (×10 6 /cm 2 of carotid artery) was reduced over 12-fold in pigs treated with FAA (13±3 versus 164±51, P =0.001) compared with placebo. Fibrin(ogen) deposition (×10 12 molecules/cm 2 of carotid artery) did not significantly differ in FAA-treated pigs versus placebo (40±8 versus 140±69, P =0.08). Large mural thrombi were present in 100% of placebo-treated pigs versus very small thrombi in 40% of FAA-treated pigs ( P =0.005). Vasoconstriction was reduced from 46±6% in the placebo group to 15±3% in the FAA group ( P <0.001). Plasma level of FAA before angioplasty was 515±23 μg/mL. The activated partial thromboplastin time was unchanged. The bleeding time was >2SD above the normal mean in 4 of 5 treated pigs (increased from 157±29 to 522±123 s). Conclusions —FAA markedly reduced platelet deposition, mural thrombi, and injury-induced vasoconstriction after deep arterial injury, suggesting that a major inhibition of platelet glycoprotein Ibα may be beneficial therapy.
BACKGROUND: Flavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA on platelet-dependent thrombosis was studied in vivo in the porcine carotid artery after deep arterial injury by balloon angioplasty. METHODS AND RESULTS: (111)In-labeled autologous platelet and (125)I-labeled porcine fibrin(ogen) deposition, and the incidence of macroscopic mural thrombosis onto deeply injured artery (tunica media) were compared in 20 pigs (40+/-1 kg [mean+/-SEM], body surface area=1.0+/-0.1 m(2)), randomized to FAA bolus (n=10) of 5.5g/m(2), followed by an infusion at 0.14g. m(-2). min(-1) or placebo (n=10). Vasoconstriction was measured immediately beyond the dilated segment using quantitative angiography. Platelet deposition (x10(6)/cm(2) of carotid artery) was reduced over 12-fold in pigs treated with FAA (13+/-3 versus 164+/-51, P=0.001) compared with placebo. Fibrin(ogen) deposition (x10(12) molecules/cm(2) of carotid artery) did not significantly differ in FAA-treated pigs versus placebo (40+/-8 versus 140+/-69, P=0.08). Large mural thrombi were present in 100% of placebo-treated pigs versus very small thrombi in 40% of FAA-treated pigs (P=0.005). Vasoconstriction was reduced from 46+/-6% in the placebo group to 15+/-3% in the FAA group (P<0.001). Plasma level of FAA before angioplasty was 515+/-23 microgram/mL. The activated partial thromboplastin time was unchanged. The bleeding time was >2SD above the normal mean in 4 of 5 treated pigs (increased from 157+/-29 to 522+/-123 s). CONCLUSIONS: FAA markedly reduced platelet deposition, mural thrombi, and injury-induced vasoconstriction after deep arterial injury, suggesting that a major inhibition of platelet glycoprotein Ibalpha may be beneficial therapy.
Flavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA on platelet-dependent thrombosis was studied in vivo in the porcine carotid artery after deep arterial injury by balloon angioplasty. (111)In-labeled autologous platelet and (125)I-labeled porcine fibrin(ogen) deposition, and the incidence of macroscopic mural thrombosis onto deeply injured artery (tunica media) were compared in 20 pigs (40+/-1 kg [mean+/-SEM], body surface area=1.0+/-0.1 m(2)), randomized to FAA bolus (n=10) of 5.5g/m(2), followed by an infusion at 0.14g. m(-2). min(-1) or placebo (n=10). Vasoconstriction was measured immediately beyond the dilated segment using quantitative angiography. Platelet deposition (x10(6)/cm(2) of carotid artery) was reduced over 12-fold in pigs treated with FAA (13+/-3 versus 164+/-51, P=0.001) compared with placebo. Fibrin(ogen) deposition (x10(12) molecules/cm(2) of carotid artery) did not significantly differ in FAA-treated pigs versus placebo (40+/-8 versus 140+/-69, P=0.08). Large mural thrombi were present in 100% of placebo-treated pigs versus very small thrombi in 40% of FAA-treated pigs (P=0.005). Vasoconstriction was reduced from 46+/-6% in the placebo group to 15+/-3% in the FAA group (P<0.001). Plasma level of FAA before angioplasty was 515+/-23 microgram/mL. The activated partial thromboplastin time was unchanged. The bleeding time was >2SD above the normal mean in 4 of 5 treated pigs (increased from 157+/-29 to 522+/-123 s). FAA markedly reduced platelet deposition, mural thrombi, and injury-induced vasoconstriction after deep arterial injury, suggesting that a major inhibition of platelet glycoprotein Ibalpha may be beneficial therapy.
Author HERAS, M
CHESEBRO, J. H
MRUK, J. S
REID, J. M
GRILL, D. E
WEBSTER, M. W. I
Author_xml – sequence: 1
  givenname: J. S
  surname: MRUK
  fullname: MRUK, J. S
  organization: Buchanan County Cardiology, PC, St. Joseph, Mo, United States
– sequence: 2
  givenname: M. W. I
  surname: WEBSTER
  fullname: WEBSTER, M. W. I
  organization: Green Lane Hospital, Epsom, Auckland, New Zealand
– sequence: 3
  givenname: M
  surname: HERAS
  fullname: HERAS, M
  organization: Hospital Clinic I Provincial de Barcelona, Spain
– sequence: 4
  givenname: J. M
  surname: REID
  fullname: REID, J. M
  organization: Department of Oncology and Comprehensive Cancer Center, Mayo Clinic and Mayo Foundation, Rochester, Minn, United States
– sequence: 5
  givenname: D. E
  surname: GRILL
  fullname: GRILL, D. E
  organization: Department of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minn, United States
– sequence: 6
  givenname: J. H
  surname: CHESEBRO
  fullname: CHESEBRO, J. H
  organization: Cardiovascular Institute, Mount Sinai Medical Center, New York, United States
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1251297$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10645930$$D View this record in MEDLINE/PubMed
BookMark eNpdkUGLFDEQhYOsuLOrd08SREQPPaY6Saf7KIOrCwuC6Dmkk2rM0JO0SXpg_oK_2ugMKJ5eVfHVo4p3Q65CDEjIc2BbgA7eMdju7r9soSrf8lY8IhuQrWiE5MMV2TDGhkbxtr0mNznva9txJZ-Qa2CdkANnG_LzbjbHatr0jbFYvKXGekffTH_G0bu3dElximtw84kmdKvFTJfZFJyxNA4XDA5DoeV7iocxZp-pCY4eTY42hlySt8XHQM1UMFGHuFCTaunNTH3Yr-lUhR79MT4ljyczZ3x20Vvy7e7D192n5uHzx_vd-4fGCi5Kw6dWOiUGhZ0cB9b3PeMwsVGoToxcWTkiQw7DqCT0PXcgBucESMWEk2zk_Ja8PvvWx36smIs--Gxxnk3AuGatWK8UZ0MFX_4H7uOaQr1Nt9B21V9AhdgZsinmnHDSS_IHk04amP4dkmaga0i1Bc11DamuvLj4ruMB3T8L51Qq8OoCmGzNPCUTrM9_uVZCOyj-C1xsnE8
CODEN CIRCAZ
CitedBy_id crossref_primary_10_1016_S0014_2999_02_02449_4
crossref_primary_10_1038_sj_bjp_0707668
crossref_primary_10_3109_13880209_2014_914957
crossref_primary_10_1016_j_thromres_2012_01_001
crossref_primary_10_18006_2023_11_4__650_662
crossref_primary_10_1016_S0165_6147_00_01885_X
crossref_primary_10_1016_j_phymed_2020_153363
crossref_primary_10_1038_sj_ejcn_1602291
crossref_primary_10_1016_j_thromres_2010_11_028
crossref_primary_10_1080_09537100500124442
crossref_primary_10_1111_j_1538_7836_2004_01099_x
crossref_primary_10_1080_09537100410001710263
crossref_primary_10_1016_j_mehy_2006_05_031
crossref_primary_10_1016_j_thromres_2008_01_014
crossref_primary_10_1111_jth_12362
Cites_doi 10.1161/circ.90.6.7994845
10.1161/circ.96.10.3281
10.1161/01.RES.57.1.105
10.1056/NEJM199607043350108
10.1111/j.1749-6632.1987.tb33073.x
10.1055/s-0038-1657598
10.1152/ajpheart.1993.265.2.H774
10.1161/01.CIR.93.4.792
10.1161/atvb.16.5.628
10.1073/pnas.91.14.6334
10.1161/circ.69.2.6606504
10.1016/0360-3016(92)90847-B
10.1002/ijc.2910490219
10.1182/blood.V71.4.831.831
10.1016/0277-5379(87)90157-X
10.1016/0277-5379(91)90185-G
10.1038/bjc.1989.348
10.1016/S0046-8177(87)80330-1
10.1161/circ.75.1.2947743
10.1182/blood.V67.5.1229.1229
10.1161/01.CIR.82.4.1476
10.1182/blood.V74.4.1181.1181
10.1126/science.2821619
10.1038/bjc.1991.382
10.3949/ccjm.63.3.181
10.1172/JCI115592
10.1016/0277-5379(89)90072-2
10.1016/0277-5379(89)90099-0
ContentType Journal Article
Copyright 2000 INIST-CNRS
Copyright American Heart Association, Inc. Jan 25, 2000
Copyright_xml – notice: 2000 INIST-CNRS
– notice: Copyright American Heart Association, Inc. Jan 25, 2000
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
NAPCQ
U9A
7X8
DOI 10.1161/01.CIR.101.3.324
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Career and Technical Education (Alumni Edition)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage 328
ExternalDocumentID 49827530
10_1161_01_CIR_101_3_324
10645930
1251297
Genre Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: HL 07111/14T
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
08R
0R~
0ZK
18M
1CY
1J1
29B
2FS
2WC
354
40H
41~
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAXR
AAEJM
AAGIX
AAHPQ
AAJCS
AAMOA
AAMTA
AAPBV
AAQKA
AARTV
AASOK
AASXQ
AAUGY
AAWTL
AAXQO
AAYOK
ABASU
ABBUW
ABDIG
ABOCM
ABPMR
ABPTK
ABQRW
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACOAL
ACRKK
ACRZS
ACWDW
ACWRI
ACXNZ
ADBBV
ADCYY
ADFPA
ADGGA
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFCHL
AFDTB
AFFNX
AFUWQ
AGINI
AHMBA
AHOMT
AHRYX
AHVBC
AIJEX
AJIOK
AJJEV
AJNWD
AJNYG
AKALU
AKULP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
ASPBG
AVWKF
AWKKM
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BS7
BYPQX
C1A
C45
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FEDTE
FL-
FW0
GNXGY
GQDEL
GX1
H0~
H13
HZ~
H~9
IKREB
IKYAY
IN~
IPNFZ
IQODW
J5H
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
M18
MVM
N4W
N9A
NEJ
N~7
N~B
N~M
O9-
OAG
OAH
OBH
OCB
OCUKA
ODA
ODMTH
OGEVE
OHH
OHT
OHYEH
OJAPA
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
R58
RAH
RHF
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
UPT
V2I
VVN
W2D
W3M
W8F
WH7
WHG
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YOC
YQJ
YSK
YXB
YYM
YYP
YZZ
ZA5
ZFV
ZGI
ZXP
ZY1
ZZMQN
~H1
AAAAV
AAIQE
AAUEB
ABJNI
ADHPY
AFEXH
AHQNM
AINUH
AJZMW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
NAPCQ
U9A
7X8
ID FETCH-LOGICAL-c434t-3f25d7497e65b90888031f0b4764b37c5be0e319b751883d149dd415704d50b33
ISSN 0009-7322
IngestDate Fri Oct 25 22:25:48 EDT 2024
Thu Oct 10 19:11:57 EDT 2024
Fri Dec 06 01:58:12 EST 2024
Wed Oct 16 00:50:49 EDT 2024
Sun Oct 29 17:08:31 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Vasoconstriction
Instrumentation therapy
Cardiovascular disease
Instrumental dilatation
Flavonoid
Thrombosis
Artery
Antiplatelet agent
Pig
Arterial disease
Vascular disease
Aggregation
Prevention
Restenosis
Vertebrata
Chemotherapy
Platelet
Mammalia
Treatment
Animal
Complication
Artiodactyla
Ungulata
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c434t-3f25d7497e65b90888031f0b4764b37c5be0e319b751883d149dd415704d50b33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.101.3.324
PMID 10645930
PQID 212675141
PQPubID 24119
PageCount 5
ParticipantIDs proquest_miscellaneous_70877309
proquest_journals_212675141
crossref_primary_10_1161_01_CIR_101_3_324
pubmed_primary_10645930
pascalfrancis_primary_1251297
PublicationCentury 2000
PublicationDate 2000-01-25
PublicationDateYYYYMMDD 2000-01-25
PublicationDate_xml – month: 01
  year: 2000
  text: 2000-01-25
  day: 25
PublicationDecade 2000
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
– name: Baltimore
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAlternate Circulation
PublicationYear 2000
Publisher Lippincott Williams & Wilkins
American Heart Association, Inc
Publisher_xml – name: Lippincott Williams & Wilkins
– name: American Heart Association, Inc
References 11157735 - Circulation. 2001 Jan 30;103(4):E23
e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_29_2
e_1_3_2_20_2
e_1_3_2_21_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_24_2
e_1_3_2_25_2
(e_1_3_2_12_2) 1987; 2
(e_1_3_2_32_2) 1990; 50
(e_1_3_2_28_2) 1994; 283
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_19_2
e_1_3_2_1_2
e_1_3_2_30_2
(e_1_3_2_5_2) 1996; 33
e_1_3_2_10_2
e_1_3_2_31_2
(e_1_3_2_8_2) 1996; 3
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
(e_1_3_2_35_2) 1996; 93
References_xml – ident: e_1_3_2_36_2
  doi: 10.1161/circ.90.6.7994845
– ident: e_1_3_2_37_2
  doi: 10.1161/circ.96.10.3281
– ident: e_1_3_2_14_2
  doi: 10.1161/01.RES.57.1.105
– ident: e_1_3_2_6_2
  doi: 10.1056/NEJM199607043350108
– ident: e_1_3_2_19_2
  doi: 10.1111/j.1749-6632.1987.tb33073.x
– ident: e_1_3_2_1_2
– ident: e_1_3_2_9_2
  doi: 10.1055/s-0038-1657598
– ident: e_1_3_2_34_2
  doi: 10.1152/ajpheart.1993.265.2.H774
– ident: e_1_3_2_17_2
  doi: 10.1161/01.CIR.93.4.792
– ident: e_1_3_2_31_2
  doi: 10.1161/atvb.16.5.628
– ident: e_1_3_2_29_2
  doi: 10.1073/pnas.91.14.6334
– ident: e_1_3_2_20_2
  doi: 10.1161/circ.69.2.6606504
– ident: e_1_3_2_33_2
  doi: 10.1016/0360-3016(92)90847-B
– volume: 3
  start-page: 12
  year: 1996
  ident: e_1_3_2_8_2
  publication-title: Sci Med
– ident: e_1_3_2_25_2
  doi: 10.1002/ijc.2910490219
– ident: e_1_3_2_3_2
  doi: 10.1182/blood.V71.4.831.831
– ident: e_1_3_2_21_2
  doi: 10.1016/0277-5379(87)90157-X
– volume: 283
  start-page: 6478
  year: 1994
  ident: e_1_3_2_28_2
  publication-title: J Biol Chem
– ident: e_1_3_2_26_2
  doi: 10.1016/0277-5379(91)90185-G
– ident: e_1_3_2_23_2
  doi: 10.1038/bjc.1989.348
– ident: e_1_3_2_2_2
  doi: 10.1016/S0046-8177(87)80330-1
– ident: e_1_3_2_16_2
  doi: 10.1161/circ.75.1.2947743
– volume: 2
  start-page: 1081
  year: 1987
  ident: e_1_3_2_12_2
  publication-title: Lancet
– ident: e_1_3_2_18_2
  doi: 10.1182/blood.V67.5.1229.1229
– volume: 93
  start-page: 1255
  year: 1996
  ident: e_1_3_2_35_2
  publication-title: Circulation
– ident: e_1_3_2_15_2
  doi: 10.1161/01.CIR.82.4.1476
– volume: 33
  start-page: 1526
  year: 1996
  ident: e_1_3_2_5_2
  publication-title: N Engl J Med
– ident: e_1_3_2_4_2
  doi: 10.1182/blood.V74.4.1181.1181
– ident: e_1_3_2_27_2
  doi: 10.1126/science.2821619
– ident: e_1_3_2_24_2
  doi: 10.1038/bjc.1991.382
– ident: e_1_3_2_10_2
– ident: e_1_3_2_7_2
  doi: 10.3949/ccjm.63.3.181
– ident: e_1_3_2_30_2
  doi: 10.1172/JCI115592
– ident: e_1_3_2_11_2
  doi: 10.1016/0277-5379(89)90072-2
– ident: e_1_3_2_13_2
– volume: 50
  start-page: 6966
  year: 1990
  ident: e_1_3_2_32_2
  publication-title: Cancer Res
– ident: e_1_3_2_22_2
  doi: 10.1016/0277-5379(89)90099-0
SSID ssj0006375
Score 1.7669418
Snippet Flavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA on...
Background —Flavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA...
BACKGROUND: Flavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA...
BACKGROUNDFlavone-8-acetic acid (FAA; [Flavonoid]), an adjuvant antitumor drug, inhibits ristocetin-induced aggregation of human platelets. The effect of FAA...
SourceID proquest
crossref
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 324
SubjectTerms Animals
Antineoplastic Agents - pharmacology
Biological and medical sciences
Blood Platelets - drug effects
Blood. Blood coagulation. Reticuloendothelial system
Catheterization
Flavonoids - pharmacokinetics
Flavonoids - pharmacology
Medical sciences
Pharmacology. Drug treatments
Platelet Glycoprotein GPIb-IX Complex - antagonists & inhibitors
Swine
Thrombosis - drug therapy
Vasoconstriction - drug effects
Title Flavone-8-acetic acid (flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury in vivo
URI https://www.ncbi.nlm.nih.gov/pubmed/10645930
https://www.proquest.com/docview/212675141
https://search.proquest.com/docview/70877309
Volume 101
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FIiEkhKDlEkphHxCiqja1s2s7fqyihoCaIlWJmjfLa49RoE2ixInUfgK_yM8ws7ZjJykIeLEjO17bOsc7l50LY-_cCGWU7brC1Q4IBSoSoefbIkFRiBIRLBco37l37nYH6vPQGdZqPytRS4tUN6LbO_NK_gdVPIa4UpbsPyC7GhQP4G_EF7eIMG7_CuPOVbicjEG0RBiBqbwajYxTIDEnJvRAPoVgJdQ86ermaEaFWmFOvaNTlDepKHrgpqZhz7WeUH0S8qUvQ4SNdMfZaL2ZOEyPTBioafYx_oaQkMtkOVpOqnpuezSL8sZgd_X7qfgferPF98yNfwtJ6Yi9BF30DKF0oqPL0r3bhVmWhdYLv5b-hAsYxdk4FKu75sygmDiRJT5X8gdCKvKFr1Jl6FZkKCmHwpNZUnMD8tm7qYRysupIq-k9d5aMqua_maxllr29LURc2yRGNNqfLsi70ZCN_K_r9brPvwSdwdlZ0D8d9tfPGv1A-a0mGoPWPXafqjRSY4ePwzL-yJWeU7T5o_co1tBd-3jz1ms606NpOMfPN8n6rvzeMDIKUv8Je5xbNvwko-lTVoPxLts7GYfp5PqGv-cm1tgs4uyyB708pGOP_dgkMScS8w8rCh_yksA8JzDfJjAvCcyRwHyTwNwQmBOBeUFgnhEYd5wI_IwNOqf9dlfkDUJEpKRKhUyaTuwp3wPX0RSw10IRlVhaea7S0oscDRagjNG0ttiSsa38OEaN1bNU7FhayudsZ4xv-JJxvALiGK0HW7eUAgjtCHzte1EIYQJ-XGeHBQTBNKsDExj72bUDyw4QLgqWDGSAcNXZwRpG5QVkTPhene0XmAX5bDIPUIVE2x3vX2dvV2dxqqf1u3AMk8U88Kh4p7T8OnuRAV15EqoJJa1Xfxx5nz0sv7nXbCedLeAAVepUvzHU_AUiZc14
link.rule.ids 314,780,784,27924,27925
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Flavone-8-acetic+acid+%28flavonoid%29+profoundly+reduces+platelet-dependent+thrombosis+and+vasoconstriction+after+deep+arterial+injury+in+vivo&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Mruk%2C+Jozef+S&rft.au=Webster%2C+Mark+W+I&rft.au=Heras%2C+Magda&rft.au=Reid%2C+Joel+M&rft.date=2000-01-25&rft.pub=American+Heart+Association%2C+Inc&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=101&rft.issue=3&rft.spage=324&rft_id=info:doi/10.1161%2F01.CIR.101.3.324&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=49827530
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon